Skylar Jeremias

A review on the effects of Janus kinase (JAK) inhibitors for the treatment of myelofibrosis, including the first approved, ruxolitinib, and others currently in development.

The impact of psoriatic arthritis on quality of life can vary depending on geographic location and culture, according to a global patient survey.

A study conducted by Mayo Clinic researchers revealed that a combined treatment featuring daratumumab in conjunction with the standard-of-care for patients with amyloid light-chain (AL) amyloidosis was more effective in improving the condition than the standard treatment alone.

Studies with better data are still needed to fully understand the epidemiology of Duchenne muscular dystrophy (DMD), according to a recently published review.

Authors of an opinion piece concluded that not only are immunosuppressed patients with psoriasis not at an increased risk of developing serious complications related to coronavirus disease 2019 (COVID-19), their medications may help mitigate potential issues.

A data analysis of real-world data found that the rise of orphan drugs (ODs) in the Republic of Korea has not solved all patient accessibility issues as budget concerns can make it difficult to justify reimbursements.

A recent analysis describes the effects of the pandemic, including restrictions on outdoor activities and loss of income, on patients with psoriasis in China earlier this year.

The presentation at Virtual ISPOR 2020 found that 7% of a group of Medicare beneficiaries with type 2 diabetes was experiencing food insecurity, a rate the lead author found "alarming."

Ruxolitinib was found to be more cost-effective than the best available therapy (BAT) when the willingness-to-pay threshold for payers was at $150,000 and applied to patients with hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly, according to a new study.

Samsung Bioepis announced positiive trial results for its ranibizumab biosimilar (SB11).

A patient’s sex, disease duration, and residence were the most common sociodemographic factors shown to affect illness acceptance, life satisfaction, sense of stigmatization, and quality of life among those who have psoriasis, according to the results of a recent study.

In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.

Platelet function may aid in determining disease severity for patients with psoriasis who are at an increased risk of developing cardiovascular disease (CVD) and increased inflammation, a review notes.

Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.

Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.

Although the results have to be confirmed in a larger clinical trial, the researchers hope that the biomarker could be a noninvasive marker of a rare pediatric liver disease.

The FDA Friday approved pemigatinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Researchers found that the factors most associated with health related quality of life (HRQOL) in patients with facial palsy are age, bilateral facial palsy, severity of facial palsy, anxiety, and key personality traits, including extraversion and emotional stability.

Despite experiencing general fears, patients with rare diseases may be the most equipped to handle the coronavirus disease 2019 (COVID-19) pandemic, according to some experts.

AHIP wants the FDA and FTC to streamline product approvals, clarify the regulations governing biosimilars, put a stop to attempts to discourage people from using biosimilars, and start educating providers and patients about the safety and efficacy of these products.

The FDA released guidance on what sponsors should take into account when trying to demonstrate clinical effectiveness of new treatments in patients with slowly progressive, low-prevalence rare diseases with substrate deposition that result from single enzyme defects.

Payers view the National Comprehensive Cancer Network (NCCN) guidelines as a gold standard for making reimbursement decisions, according to a panel of experts who spoke recently about biosimilar uptake.

Cushing syndrome, a rare endocrine disorder caused by abnormally excessive amounts of the hormone cortisol, has a new pharmaceutical treatment to treat cortisol overproduction.

The analysis looked at 13 of America’s largest employers, including energy, hospitality, retail, transportation, and finance companies.

Limited data about the effects of psoriasis therapy during pregnancy make it difficult to know which options are possible for pregnant patients and which ones can be harmful, according to a review.

An expert panel discussed the systemic and policy barriers to the uptake of biosimilars.

The results are in line with earlier studies, and the current review found a link with bladder cancer and lung cancer.

Investigators say that inconsistencies in the way rare diseases are defined contribute to misdiagnoses, delayed treatment, and other ills that could be addressed with global standards.